Fig. 10 | Scientific Reports

Fig. 10

From: ASCL2 contributes to clinical assessments of breast cancer and mediates tumor progression via the interaction with CLDN3

Fig. 10

An underlying oncogenic mechanism of ASCL2 in breast cancer. (A) Transfection efficiency of the recombinant vectors of CLDN3; (B-E) The interaction of ASCL2 and CLDN3 as confirmed by Co-IP assays; (F-I) ASCL2 and CLDN3 can mutually affect each other’s ability to promote the proliferation of BC cells; (J-M) ASCL2 and CLDN3 can mutually affect each other’s ability to promote the migration and invasion of BC cells; IP, immunoprecipitation; HC, heavy chain; LC, light chain; **P < 0.01, ***P < 0.001.

Back to article page